The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G
British Journal of Clinical Pharmacology (1995)
A criteria-based meta-analysis of 24 HCG-for-obesity trials found that 11 of the 12 methodologically adequate studies reported no effect of HCG on weight loss, fat redistribution, hunger, or sense of well-being — the load-bearing negative result behind the modern medical consensus that the Simeons HCG diet does not work.
This is the criteria-based meta-analysis that anchors the modern medical-literature consensus against the Simeons HCG diet — a low-calorie weight-loss protocol introduced by British endocrinologist Albert T.W. Simeons in the mid-1950s that paired daily injections of human chorionic gonadotropin with a 500-kcal/day restriction and claimed effects on appetite, fat-localization-pattern, and well-being that pure caloric restriction was alleged not to produce. By the 1970s the protocol had become a fixture of commercial weight-loss clinics in the United States and Europe; by the 1990s the FDA had required Simeons-style HCG products to carry an explicit no-evidence-of-weight-loss-efficacy warning, but the practitioner and direct-to-consumer markets continued to operate at substantial scale.
Lijesen and colleagues at the Vrije Universiteit Amsterdam Department of General Practice conducted a systematic literature review, identifying via computer-aided search and citation tracking 24 controlled and uncontrolled trials of HCG in the treatment of obesity. Each study was scored on a prespecified methodological-quality scale capturing randomization, blinding, comparability of treatment and control arms, intention-to-treat handling, and outcome-measurement standardization — a criteria-based approach designed to weight high-quality studies above the older case-series and uncontrolled-design literature on which Simeons-protocol proponents typically relied.
Twelve of the 24 trials cleared the methodological-adequacy threshold. Of those 12, eleven reported no statistically or clinically significant effect of HCG on the four outcomes most commonly claimed for the Simeons protocol: weight loss, fat-redistribution pattern, hunger reduction, and sense of well-being. The single dissenting trial was not sufficient to overturn the pattern. The authors concluded that there was no scientific evidence supporting the use of HCG in the treatment of obesity and that the persistent commercial and practitioner deployment of the Simeons protocol did not reflect the evidence base. The conclusion has been corroborated by subsequent independent reviews, and the paper remains the most-cited single reference behind the modern position. Cross-link to the HCG peptide page for the broader hormonal-physiology context (the molecule has separate and legitimate roles in fertility medicine and in male hypogonadism on the testosterone-maintenance literature surveyed in Coviello et al. 2005 and Habous et al. 2018, which are entirely distinct from the diet-protocol claim addressed here).
The 24-study evidence base reviewed in 1995 is now three decades old; the absence of subsequent positive trials in the intervening period strengthens the original finding rather than weakening it — the Simeons-protocol literature did not develop into a positive evidence base after the meta-analysis, and the major subsequent reviews (the 2009 American Journal of Medicine review by Mehta and Bredenkamp; the 2012 FDA enforcement action against homeopathic-HCG diet products) all reaffirm the absence of efficacy. The criteria-based methodology preceded modern PRISMA guidelines and Cochrane-handbook synthesis standards by about a decade, but the underlying quality-scoring is transparent and reproducible. Industry independence is high — the authors were affiliated with a Dutch academic general-practice department with no disclosed commercial ties to either Simeons-protocol proponents or to weight-loss alternatives. The meta-analysis does not address the legitimate clinical uses of human chorionic gonadotropin in fertility medicine, in the diagnosis and treatment of hypogonadotropic hypogonadism, or in the maintenance of testicular function during exogenous testosterone administration — those indications rest on entirely separate evidence bases and are surveyed elsewhere in the corpus. The honest reading: the Simeons HCG diet does not work for weight loss, and the molecular biology of human chorionic gonadotropin (an LH-mimetic glycoprotein hormone that supports luteal-phase progesterone and Leydig-cell testosterone synthesis) does not predict appetite or fat-redistribution effects in the first place. The protocol's persistence is a sociology-of-medicine phenomenon rather than a pharmacology phenomenon.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.